Macleods Pharmaceuticals Limited
Macleods Pharmaceuticals Limited, a prominent player in the global pharmaceutical industry, is headquartered in India. Founded in 1986, the company has established a strong presence in various operational regions, including North America, Europe, and Africa. Specialising in the development, manufacturing, and marketing of generic pharmaceuticals, Macleods offers a diverse portfolio that includes formulations across multiple therapeutic areas such as oncology, cardiology, and anti-infectives. With a commitment to quality and innovation, Macleods Pharmaceuticals has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is recognised for its robust research and development capabilities, which enable it to deliver unique and effective healthcare solutions. As a result, Macleods has secured a notable position in the market, contributing to improved patient outcomes globally.
DitchCarbon Score
How does Macleods Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Macleods Pharmaceuticals Limited's score of 17 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Macleods Pharmaceuticals Limited's reported carbon emissions
In 2023, Macleods Pharmaceuticals Limited reported total carbon emissions of approximately 1,778,430 kg CO2e. This figure includes 740 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources. Scope 2 emissions, related to the generation of purchased electricity, amounted to about 530 kg CO2e (market-based) and 300 kg CO2e (location-based). The majority of their emissions, approximately 1,777,160 kg CO2e, fall under Scope 3, which encompasses indirect emissions from the value chain. Currently, Macleods Pharmaceuticals has not set specific reduction targets or initiatives, nor do they participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of formal commitments indicates a potential area for growth in their climate strategy. As the pharmaceutical industry increasingly focuses on sustainability, Macleods Pharmaceuticals may benefit from establishing clear emissions reduction goals to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 740 |
| Scope 2 | 530 |
| Scope 3 | 1,777,160 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Macleods Pharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
